Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less
Brief Summary: The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.


Options:
A: Arm Label: EZ/Simva 10/40 mg; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe (+) simvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: ezetimibe (+) simvastatin; Assigned to Arm(s): EZ/Simva 10/40 mg | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Pooled subjects who received ezetimibe with simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe with simvastatin | Arm Label: Pooled subjects who received simvastatin monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Intervention Type: DRUG; Name: ezetimibe with simvastatin; Assigned to Arm(s): Pooled subjects who received ezetimibe with simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): Pooled subjects who received simvastatin monotherapy
C: Arm Label: LZ group; Type: EXPERIMENTAL; Interventions: Drug: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe] | Arm Label: L group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lipitor (Atorvastatin) monotherapy | Intervention Type: DRUG; Name: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]; Assigned to Arm(s): LZ group | Intervention Type: DRUG; Name: Lipitor (Atorvastatin) monotherapy; Assigned to Arm(s): L group
D: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Placebo QM; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Ezetimibe (Q2W); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Biological: Placebo to Evolocumab | Arm Label: Ezetimibe (QM); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Biological: Placebo to Evolocumab | Arm Label: Evolocumab Q2W; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Other: Placebo to Ezetimibe | Arm Label: Evolocumab QM; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Other: Placebo to Ezetimibe | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab Q2W, Evolocumab QM | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe (Q2W), Ezetimibe (QM) | Intervention Type: BIOLOGICAL; Name: Placebo to Evolocumab; Assigned to Arm(s): Ezetimibe (Q2W), Ezetimibe (QM), Placebo Q2W, Placebo QM | Intervention Type: OTHER; Name: Placebo to Ezetimibe; Assigned to Arm(s): Evolocumab Q2W, Evolocumab QM, Placebo Q2W, Placebo QM

Answer: D